Pharmaceutical Technologies Co (PT) is a developer and manufacturer of medical drugs in Beeland. Itis one of the 100 largest listed companies on the national stock exchange. The company focuses on buyingprospective drugs that have shown initial promise in testing from small bio-engineering companies. PT thenleads these through three regulatory stages to launch in the general medical market. The three stages are:1. to confirm the safety of the drug (does it harm humans?), in small scale trials;2. to test the efficacy of the product (does it help cure?), again in small scale trials; and3. finally, large scale trials to definitively decide on the safety and efficacy of the product.The drugs are then marketed through the company's large sales force to health care providers and end users(patients). The health care providers are paid by either health insurance companies or the nationalgovernment dependent on the financial status of the patient.The Beeland Drug Regulator (BDR) oversees this testing process and makes the final judgement aboutwhether a product can be sold in the country.Its objectives are to protect, promote and improve public health by ensuring that:- medicines have an acceptable balance of benefit and risk;- the users of these medicines understand this risk-benefit profile; and- new beneficial product development is encouraged.The regulator is governed by a board of trustees appointed by the government. It is funded directly by thegovernment and also through fees charged to drug companies when granting licences to sell their productsin Beeland.PT has used share price and earnings per share as its principal measures of performance to date. However,the share price has underperformed the market and the health sector in the last two years. The chiefexecutive officer (CEO) has identified that these measures are too narrow and is considering implementinga balanced scorecard approach to address this problem.A working group has drawn up a suggested balanced scorecard. It began by identifying the objectives fromthe board's medium term strategy:- Create shareholder value by bringing commercially viable drugs to market- Improve the efficiency of drug development- Increase shareholder value by innovation in the drug approval processThe working group then considered the stakeholder perspectives:- Shareholders want a competitive return on their investment- Purchasers (governments, insurers and patients) want to pay a reasonable price for the drugs- Regulators want an efficient process for the validation of drugs- Doctors want safe and effective drug products- Patients want to be curedFinally, this leads to the proposed scorecard of performance measures:- Financial - share price and earnings per share- Customer - number of patients using PT products- Internal business process - exceed industry-standard on design and testing; time to regulatoryapproval of a product- Learning and growth - training days undertaken by staff; time to market of new product; percentage ofdrugs bought by PT that gain final approval.The balanced scorecard now needs to be reviewed to ensure that it will address the company's objectivesand the issues that it faces in its business environment. Required:(a) Evaluate the performance measures proposed for PT's balanced scorecard. b) Briefly decsribe a method of analysing stakeholder influence and analyses the influence of four different external stakeholders on the regulator (BDR). (c) Using your answer from part b, describe how the application of the balanced scorecard approach at BDR would differ from the approach within PT.

Question

Pharmaceutical Technologies Co (PT) is a developer and manufacturer of medical drugs in Beeland. Itis one of the 100 largest listed companies on the national stock exchange. The company focuses on buyingprospective drugs that have shown initial promise in testing from small bio-engineering companies. PT thenleads these through three regulatory stages to launch in the general medical market. The three stages are:1. to confirm the safety of the drug (does it harm humans?), in small scale trials;2. to test the efficacy of the product (does it help cure?), again in small scale trials; and3. finally, large scale trials to definitively decide on the safety and efficacy of the product.The drugs are then marketed through the company's large sales force to health care providers and end users(patients). The health care providers are paid by either health insurance companies or the nationalgovernment dependent on the financial status of the patient.The Beeland Drug Regulator (BDR) oversees this testing process and makes the final judgement aboutwhether a product can be sold in the country.Its objectives are to protect, promote and improve public health by ensuring that:- medicines have an acceptable balance of benefit and risk;- the users of these medicines understand this risk-benefit profile; and- new beneficial product development is encouraged.The regulator is governed by a board of trustees appointed by the government. It is funded directly by thegovernment and also through fees charged to drug companies when granting licences to sell their productsin Beeland.PT has used share price and earnings per share as its principal measures of performance to date. However,the share price has underperformed the market and the health sector in the last two years. The chiefexecutive officer (CEO) has identified that these measures are too narrow and is considering implementinga balanced scorecard approach to address this problem.A working group has drawn up a suggested balanced scorecard. It began by identifying the objectives fromthe board's medium term strategy:- Create shareholder value by bringing commercially viable drugs to market- Improve the efficiency of drug development- Increase shareholder value by innovation in the drug approval processThe working group then considered the stakeholder perspectives:- Shareholders want a competitive return on their investment- Purchasers (governments, insurers and patients) want to pay a reasonable price for the drugs- Regulators want an efficient process for the validation of drugs- Doctors want safe and effective drug products- Patients want to be curedFinally, this leads to the proposed scorecard of performance measures:- Financial - share price and earnings per share- Customer - number of patients using PT products- Internal business process - exceed industry-standard on design and testing; time to regulatoryapproval of a product- Learning and growth - training days undertaken by staff; time to market of new product; percentage ofdrugs bought by PT that gain final approval.The balanced scorecard now needs to be reviewed to ensure that it will address the company's objectivesand the issues that it faces in its business environment. Required:(a) Evaluate the performance measures proposed for PT's balanced scorecard. b) Briefly decsribe a method of analysing stakeholder influence and analyses the influence of four different external stakeholders on the regulator (BDR). (c) Using your answer from part b, describe how the application of the balanced scorecard approach at BDR would differ from the approach within PT.

Accepted Answer

(a) Evaluation of performance measures proposed for PT's balanced scorecard.
The financial…